Total Payments
$1.3M
2024 Payments
$209,459
Companies
26
Transactions
1,169
Medicare Patients
869
Medicare Billing
$102,705
Payment Breakdown by Category
Other$759,168 (56.6%)
Consulting$422,120 (31.4%)
Travel$132,143 (9.8%)
Food & Beverage$27,952 (2.1%)
Education$1,050 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $543,885 | 151 | 40.5% |
| Consulting Fee | $422,120 | 115 | 31.4% |
| Travel and Lodging | $132,143 | 346 | 9.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $96,350 | 27 | 7.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $69,030 | 18 | 5.1% |
| Honoraria | $49,903 | 20 | 3.7% |
| Food and Beverage | $27,952 | 491 | 2.1% |
| Education | $1,050 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $408,004 | 387 | $0 (2024) |
| ABBVIE INC. | $247,668 | 290 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $184,008 | 130 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $172,435 | 114 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $83,302 | 20 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $72,371 | 34 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $64,485 | 88 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $28,186 | 29 | $0 (2017) |
| Shionogi Inc | $18,552 | 10 | $0 (2022) |
| Madrigal Pharmaceuticals | $17,166 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $209,459 | 153 | Gilead Sciences, Inc. ($82,601) |
| 2023 | $105,326 | 88 | INTERCEPT PHARMACEUTICALS, INC. ($45,261) |
| 2022 | $112,639 | 85 | Gilead Sciences, Inc. ($62,702) |
| 2021 | $189,250 | 125 | Gilead Sciences, Inc. ($75,855) |
| 2020 | $141,661 | 85 | AbbVie Inc. ($58,795) |
| 2019 | $192,512 | 201 | Gilead Sciences, Inc. ($68,316) |
| 2018 | $189,825 | 226 | Merck Sharp & Dohme Corporation ($65,362) |
| 2017 | $201,761 | 206 | Merck Sharp & Dohme Corporation ($86,825) |
All Payment Transactions
1,169 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $58.50 | General |
| Category: HBV | ||||||
| 12/17/2024 | Echosens North America, Inc. | FibroScan (Device) | Food and Beverage | Cash or cash equivalent | $16.48 | General |
| Category: Elastography | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: INFLAM | ||||||
| 12/16/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $128.17 | General |
| Category: Gastroenterology | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,440.00 | General |
| Category: INFLAM | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HBV | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $124.44 | General |
| Category: INFLAM | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $130.08 | General |
| Category: HBV | ||||||
| 12/03/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: VIROLOGY | ||||||
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $2,523.00 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $96.44 | General |
| 11/19/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $39.03 | General |
| 11/18/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
| 11/15/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $44.47 | General |
| Category: VIROLOGY | ||||||
| 11/14/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Rare Disease | ||||||
| 11/12/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: INFLAM | ||||||
| 11/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $126.32 | General |
| Category: LIVER DISEASE | ||||||
| 11/08/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $42.81 | General |
| Category: HBV | ||||||
| 11/08/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $130.08 | General |
| Category: INFLAM | ||||||
| 11/06/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $543.95 | General |
| Category: INFLAM | ||||||
| 11/06/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $120.66 | General |
| Category: Rare Disease | ||||||
| 11/06/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $58.59 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 179 | 210 | $69,992 | $25,864 |
| 2022 | 6 | 171 | 179 | $73,593 | $18,552 |
| 2021 | 7 | 252 | 281 | $136,442 | $31,113 |
| 2020 | 7 | 267 | 294 | $141,692 | $27,176 |
Total Patients
869
Total Services
964
Medicare Billing
$102,705
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 95 | $20,626 | $9,057 | 43.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $23,715 | $8,776 | 37.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $13,020 | $4,161 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $8,432 | $2,520 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 19 | $4,199 | $1,350 | 32.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 42 | $10,680 | $3,882 | 36.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $12,728 | $3,409 | 26.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $12,833 | $2,882 | 22.5% |
| 43244 | Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | Facility | 2022 | 14 | 14 | $19,237 | $2,834 | 14.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 33 | 35 | $8,710 | $2,477 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 14 | $4,600 | $1,632 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 19 | $4,505 | $1,391 | 30.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 15 | 15 | $300.00 | $44.61 | 14.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 55 | $15,878 | $5,950 | 37.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 29 | 29 | $21,041 | $5,590 | 26.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 38 | 38 | $26,321 | $5,461 | 20.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 54 | 62 | $15,500 | $5,128 | 33.1% |
| 43244 | Tying of dilated veins of stomach and/or esophagus using an endoscope | Facility | 2021 | 13 | 18 | $27,090 | $3,512 | 13.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 20 | $9,879 | $2,287 | 23.1% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 21 | 21 | $16,485 | $1,739 | 10.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 16 | $3,808 | $1,379 | 36.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 21 | 22 | $440.00 | $66.00 | 15.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 31 | 31 | $22,507 | $5,488 | 24.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 68 | 81 | $20,250 | $5,392 | 26.6% |
| 43244 | Tying of dilated veins of stomach and/or esophagus using an endoscope | Facility | 2020 | 19 | 21 | $31,605 | $4,060 | 12.8% |
About Dr. Steven Flamm, MD
Dr. Steven Flamm, MD is a Gastroenterology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912937244.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Flamm, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $209,459 received in 2024. These payments were reported across 1,169 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($543,885).
As a Medicare-enrolled provider, Flamm has provided services to 869 Medicare beneficiaries, totaling 964 services with total Medicare billing of $102,705. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Chicago, IL
- Active Since 07/03/2006
- Last Updated 07/06/2009
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1912937244
Products in Payments
- Epclusa (Drug) $173,040
- OCALIVA (Drug) $155,941
- MAVYRET (Drug) $107,746
- XIFAXAN (Drug) $92,546
- Vemlidy (Drug) $75,007
- Mavyret (Drug) $70,101
- IQIRVO (Drug) $52,946
- Viekira (Drug) $31,493
- Livdelzi (Drug) $27,261
- OCA (Drug) $24,767
- ZEPATIER (Drug) $22,081
- REZDIFFRA (Drug) $17,122
- Mulpleta (Drug) $12,465
- Doptelet (Drug) $9,857
- TERLIVAZ (Drug) $8,411
- Vosevi (Drug) $6,725
- Bylvay (Drug) $3,250
- Harvoni (Drug) $680.00
- RESMETIROM (Drug) $44.79
- ENTYVIO (Biological) $39.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Chicago
Stephen Hanauer, Md, MD
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
David Rubin
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
Dr. Darren Brenner, M.d, M.D
Gastroenterology — Payments: $1.4M
Gastroenterology $1.4M
Russell Cohen
Gastroenterology — Payments: $834,887
Gastroenterology $834,887
Atman Shah
Gastroenterology — Payments: $766,122
Gastroenterology $766,122
Dr. Parambir Dulai, M.b.b.s, M.B.B.S
Gastroenterology — Payments: $614,180
Gastroenterology $614,180